Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would rather buy shares in Enron as
SNGX does so many reverse splits an investor could not get an actual paper certificate of SNGX as the transfer company couldn't keep up with them.
@Zardiw thinks it's a buy.
Though he won't buy any.
The CEO has no desire to buy shares and nor should he. He does not need to because of managements option/warrant structure.
Dor changed to Soligenix and should now consider changing the name/stock symbol to something for fitting of the times, crap/CRAP
SCHABER: Buy back some shares to "increase shareholder value"...
Not continuous REVERSE SPLITS where only YOU benefit !!!
I will research legal actions along with all other victims...
Is the vote a simple "yes or no" without knowing the ratio of the reverse split?
A R/S was obviously coming, but I'd like to know the ratio.
I saw in the 4/29 prospectus that it would be "from 1:2 to 1:20" but anything under 1:10 probably won't keep it above $1 for long. Reverse splits suck.
And it won't stop.
SNGX is just another paycheck for management.
SNGX PR 5/23/24:"Soligenix urges stockholders to vote FOR reverse-split"!
FU Shaber - you're a disgrace to the Medical Research community !
How & why Jim Cramer would every prmote your fake business !
Yep there it is SNGX:
Page 3 of 60. (skank Schaber...)
"The Board of Directors recommends that you vote FOR this proposal because the Board of Directors believes that, if
the number of shares of Common Stock cast is insufficient to constitute a quorum or approve any proposal, it is in the
best interests of the stockholders to enable the Board of Directors to continue to seek to obtain a sufficient number of
additional votes to constitute a quorum or approve the proposals, including the Reverse Stock Split Proposal."
Uh huh? And? The stock price is primed now for the next reverse split.
How many investors in SNGX have made bank?
Not me, that's for sure.
Used to like the ex CFO over 12 years ago, or how many reverse splits?
Even took place in a stock offering as this company had so much potential.
Better to invest money in a tank of gasoline or bag of potato chips as that investment will surely appreciate in value.
SNGX seems legit with "$7.1m cash on 3/31/2024"? But PPS ???
"Dr. Schaber continued, "With approximately $7.1 million in cash at March 31, 2024, exclusive of the approximate $4.3 million in net proceeds from our recent financing and our non-dilutive government funding, we continue to manage cash burn very carefully to achieve our near-term milestones. We have a clear vision for the future, and we are actively pursuing new opportunities to create long-term value for our shareholders including but not limited to, partnership and merger and acquisition opportunities."
Soligenix Recent Accomplishments
1) On April 25, 2024, the Company announced it had received notice of intent to grant additional patents based on its patent application titled "Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines" in the United Kingdom and South Africa, with other international jurisdictions pending. To view this press release, please click here.
2) On April 18, 2024, the Company announced the pricing of its public offering of 11,875,000 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 11,875,000 shares of common stock at a combined public offering price of $0.40 per share and accompanying warrants for aggregate gross proceeds of approximately $4.75 million, before deducting placement agent fees and other offering expenses. To view this press release, please click here.
3) On April 15, 2024, the Company announced the Office of Orphan Products Development of the U.S. FDA had granted orphan drug designation to the active ingredient in SuVax™, the subunit protein vaccine of recombinantly expressed SUDV glycoprotein, for "the prevention and post-exposure prophylaxis against SUDV infection." To view this press release, please click here.
4) On April 11, 2024, the Company announced the Office of Orphan Products Development of the U.S. FDA had granted orphan drug designation to the active ingredient in MarVax™, the subunit protein vaccine of recombinantly expressed MARV glycoprotein, for "the prevention and post-exposure prophylaxis against MARV infection." To view this press release, please click here.
5) On April 3, 2024, the Company announced it had received agreement from the EMA on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte™ (synthetic hypericin) in the treatment of CTCL patients with early-stage disease. To view this press release, please click here.
Financial Results – Quarter Ended March 31, 2024
- Soligenix's revenues for the quarter ended March 31, 2024 were $0.1 million as compared to $0.3 million for the quarter ended March 31, 2023. Revenues primarily relate to government contracts and grants awarded in support of SGX943 for treatment of emerging and/or antibiotic-resistant infectious diseases; development of CiVax™, our vaccine candidate for the prevention of COVID-19, and evaluation of HyBryte™ for expanded treatment in patients with early-stage CTCL.
- Soligenix's net loss was $1.9 million, or ($0.18) per share, for the quarter ended March 31, 2024, as compared to $1.0 million, or ($0.36) per share, for the quarter ended March 31, 2023. The increase in net loss was primarily due to the recognition of an income tax benefit during the three months ended March 31, 2023 with no corresponding income tax benefit recognized during the three months ended March 31, 2024.
- Research and development expenses were $1.1 million as compared to $0.9 million for the quarters ended March 31, 2024 and 2023, respectively. The increase was primarily due to an increase in preliminary costs associated with the anticipated initiation of our Phase 2 study in Behçet's Disease and the second confirmatory Phase 3 CTCL trial.
- General and administrative expenses were $1.0 million and $1.2 million for the quarters ended March 31, 2024 and 2023, respectively. This decrease in general and administrative expenses is primarily attributable to a reduction in legal and professional fees associated with the reverse stock split of our issued and outstanding shares of common stock during the three months ended March 31, 2023.
- As of March 31, 2024, the Company's cash position, exclusive of the approximate $4.3 million in net proceeds from our recent financing, was approximately $7.1 million."
GLTA
...
..
.
Which specific scanners do you compare to DDAmanda to declare that " #DDAmanda is the BEST Scanner to find runners.....nothing out there even comes close....." ?
Watching today...now what? TIVC down 61%,, EVNB is down, SLNH is down, REBN up 2% ($0.06) after yesterday's $1 gap-up that you reported after close yesterday.
These are your DDAmanda examples of pre-breakout moves, that were in fact all provided after breakouts.
"Watch these tomorrow", you said yesterday.
Your implication that all 4 stocks from your DDAamanda scans show ready for entry.
.
Nothing you've provided is reasonable. Your DDAmanda scan examples all already broke out.
Same as all your others.
Neither........
Z
I give up............seems there's no reasoning with you.........
Z
All of them at one time or another..........
Z
All breakouts already. Again. Though, ENVB and SLNH candles are twitchin'.
Which of these have you purchased?
Which of these have you purchased?
Watch these tomorrow: ENVB, REBN, SLNH, TIVC
Z
I explained how it works in a previous post below.
Keep an eye on $IDGR.......it's going back and forth now, but we found that with a #DDAmanda Scan.........and she will run soon..
Mark this post.
We also found $CBMJ.......go look at the history and my posting history on that one.....
Also watch $LYRA......that came up on a 200Day Low Scan.
Bottom Line: #DDAmanda is the BEST Scanner to find runners.....nothing out there even comes close.....
Z
No........we run the scans every day.......lots of stocks show up.........and I just illustrate some of them when they run is all........And show how guys could have made money by buying them (after doing some DD to see their viability) the next day or sometimes in the next days.....
The #DDAmanda Charts clearly show this........
The only way to tell if a stock will run is by the activity/trading.
If a stock has a high Fact for instance, that shows uncommon interest in the stock, and lots of times they run subsequently.
Also, the 200Day Low Scan shows stocks at a bottom......if they are channeling there, they will invariably go up.
#DDAmanda finds all of these..........
We also have a Golden Cross scan that's pretty interesting. It actually PREDICTS that a Golden Cross will occur........and how fast it's approaching.......
Also have a 7-10 MA Day scan, for more advanced traders.....
Z
No, your scans find stocks after they breakout. The data then shows what each your scans is set to find, as data that has already occurred, thus after they have broken out.
You then post erroneously to claim (a lie) you found the stock before the breakout, yet only posted by you after the breakout.
Proof? Every one of your iHub DDAmanda board posts as stocks, along with their prior data shown, only after their breakout.
Proof? Go ahead. Show us:
Show us your next 15 to 20 iHub posts, that show each of your next 15 to 20 of your DDAmanda found selections before each stock actually does its breakout.
Based on your years of iHub DDAmanda board posts, that would be to show us the day before, maybe two days before.
All your iHub posts show the breakout the day of, or next day.
So, go ahead, show us that your system actually works, and you're not giving us after-the-fact finings that you only claim as known prior, and post your next 15-20 iHub DDAmanda board posts of stocks that will break out the very next day, or the next two days. 15 to 20 stocks, one after the other, to show consistency of your claims.
.
lol. Agreed. Found after they breakout, when you run the scans, after the breakout. lol
SNGX sure showing breakdown !
Sorry..........that should have been $IDGR.......
Z
No. We find them when we run our scans.......lol
Z
I post charts of breakouts, that have previously been found by the #DDAmanda scanner .......which is clearly shown on the charts I post.....
Z
Yeah, but you find them after they run.
Yeah, but your scans only find post-breakouts, which of course also shows the data from days prior. But data you don't find until after the breakout. Right? Right.
Look.....I originally wrote #DDAmanda for myself. Cause there was nothing out there (and there still isn't) that would do the things I wanted it to do. I shared it with some friends, who kept saying I should put her online.......so eventually I did. And here we are.......there's been a lot of things added over the years........and she's still the best tool for finding runners that there is.........
Z
Right......however you can clearly see the signals Before they broke out........lol
Z
They are just part of the team.....we have others on our group........
Z
every DDAmanda post you've provided shows breakout already occurred.
Looks like you're bluffing. You claim DDAmanda scans show stocks right before they run. yet you consistently and every time show stock scans that just broke out.
So your paying DDAmanda customers is the DDAmanda team?
Hold up. So your paying subscribers is the team you refer to as "we" when you refer to DDAmanda doing something like making a post of a stock pick. So, the "we" is in fact only you making a stock pick post.
So you need paying DDAmanda subscribers to make up the DDAmanda team.
No. The scans show possibilities before they run. Of course you have to do the research on them, but invariably they will run based on the scans.......
Z
Yes......we have a membership group.............
Z
Your software scans only show them after they've run. Your DDAmanda doesn't show before stocks have run.
Your examples of runners are what you did find with #DDAmanda but found only after they ran.
You say "we." There's a team of you at DDAmanda?
They really aren't picks.......just examples of runners you could have found with #DDAmanda........
Z
More........and occasionally we do post picks.........like $IDGR for instance.......
Z
So you're not in-heavy on any DDAmanda board-posted picks.
Just in heavy on some no news pick that you have inside information on, that also you've never posted a DDAmanda chart along with notations that you do with hundreds of other tickers.
What's heavy, $1,000?
Can't buy them all.......currently in heavy on $IDGR ......now you have a pick that hasn't run ........yet.......
Z
You specifically recommended SNGX. Then you re-emphasized your recommendation.
Yet you don't buy your own called-out recommendations.
LOL.
As for your DD Amanda "picks" as found from your software, you list them on ihub only after they breakout.
I bet you're full of misleading claims.
As long as those running the company keep getting their pay check and options this company will continue to do stock offerings until the count is high and the price low.
Then it will r/s...over and over and over.
Rivax was/is a joke
It all is a joke
I miss the days when one of management had a breakdown on the elevator at the FDA meeting, and had all that drama. At least it was entertaining as it was disappointing.
I don't buy every one of my recos.......and a lot of those aren't recos......they're examples of how #DDAmanda finds winners.........
Z
Does SNGX 5/22 meeting doc show potential r/s? Again?
Well, I think your answer speaks for itself about your recommendations.
Followers
|
211
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
9810
|
Created
|
06/06/06
|
Type
|
Free
|
Moderators |
SNGX [NASD] |
Soligenix, Inc. |
Healthcare | Biotechnology | USA |
Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company.
The Company is focused on developing and commercializing products to treat rare diseases.
The Company operates through two business segments:
Specialized BioTherapeutics and Public Health Solution. Soligenix’s Specialized BioTherapeutics business segment is developing
a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma (CTCL).
The Public Health Solutions business segment includes active development programs for RiVax,
its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious disease.
CTCL is its innate defense regulator technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
Soligenix has expertise in the development of orphan and unmet medical need indications including preclinical, manufacturing, regulatory and clinical expertise.
Soligenix has expertise in the development of orphan and unmet medical need indications including preclinical, manufacturing, regulatory and clinical expertise.
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
---|---|---|---|---|
HyBryte™ for Cutaneous T-Cell Lymphoma (CTCL) | ||||
| | | | |
SGX942 for Oral Mucositis Treatment | ||||
| | | | |
SGX203 for Pediatric Crohn’s Disease | ||||
| | | | |
SGX201 for Radiation Enteritis Treatment | ||||
| | | | |
Orphan and/or Fast Track Designation
Soligenix has a number of Public Health programs, funded entirely by government grants and contracts, which focus on infectious disease and biodefense applications, including our most advanced vaccination program to prevent ricin poisoning.
Proof-of-Concept | IND | Phase 1 | Phase 2/3 | Market |
---|---|---|---|---|
RiVax® to Prevent Ricin Poisoning | ||||
| | | | |
SGX943 for Infectious Disease | ||||
| | | | |
ThermoVax®: Thermostabilized Vaccines for Global Use | ||||
| | | | |
Orphan and/or Fast Track Designation
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
---|---|---|---|---|
HyBryte™ for Cutaneous T-Cell Lymphoma (CTCL) almost done [in phase 3] | ||||
| | | | |
SGX942 for Oral Mucositis Treatment almost done [in phase 3] | ||||
| | | | |
SGX203 for Pediatric Crohn’s Disease [phase 2 almost done] | ||||
| | | | |
SGX201 for Radiation Enteritis Treatment [phase 1 going into phase 2] |
Proof-of-Concept | IND | Phase 1 | Phase 2/3 | Market |
---|---|---|---|---|
RiVax® to Prevent Ricin Poisoning | ||||
| | | | |
SGX943 for Infectious Disease | ||||
| | | | |
ThermoVax®: Thermostabilized Vaccines for Global Use | ||||
| | | | |
Orphan and/or Fast Track Designation
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |